Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics
RLMD Price/Volume Stats
| Current price | $3.86 | 52-week high | $7.22 |
| Prev. close | $3.91 | 52-week low | $2.36 |
| Day low | $3.75 | Volume | 114,500 |
| Day high | $3.96 | Avg. volume | 251,320 |
| 50-day MA | $5.18 | Dividend yield | N/A |
| 200-day MA | $3.68 | Market Cap | 116.47M |
RLMD Stock Price Chart Interactive Chart >
Relmada Therapeutics, Inc. (RLMD) Company Bio
Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.
Latest RLMD News From Around the Web
Below are the latest news stories about RELMADA THERAPEUTICS INC that investors may wish to consider to help them evaluate RLMD as an investment opportunity.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call TranscriptRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript November 9, 2023 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.95. Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, […] |
Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial ResultsProgress in Clinical Development and Financial Highlights |
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023. The Company will host a conference call today, Wednesday, November 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time. |
Positive Signs As Multiple Insiders Buy Relmada Therapeutics StockGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Wednesday, November 8, 2023. |
RLMD Price Returns
| 1-mo | -17.70% |
| 3-mo | 6.34% |
| 6-mo | 29.10% |
| 1-year | 45.11% |
| 3-year | -89.66% |
| 5-year | -48.94% |
| YTD | -6.76% |
| 2023 | 18.62% |
| 2022 | -84.51% |
| 2021 | -29.75% |
| 2020 | -17.77% |
| 2019 | 747.83% |
Loading social stream, please wait...